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The prevalence of the metabolically healthy
obese phenotype in an aging population and its
association with subclinical cardiovascular
disease: The Brazilian study on healthy aging
Lara Roberson1, Sameer Shaharyar2, Ehimen Aneni1, Wladimir Freitas3, Michael Blaha4, Arthur Agatston1,
Roger Blumenthal4, Raul D Santos5, Hamid Feiz2, Khurram Nasir1,6,7,8* and Andrei Sposito9

Abstract
Background: Current literature has elucidated a new phenotype, metabolically healthy obese (MHO), with risks of
cardiovascular disease similar to that of normal weight individuals. Few studies have examined the MHO phenotype
in an aging population, especially in association with subclinical CVD.
Research design and methods: This cross sectional study population consisted of 208 octogenarians and older.
Anthropometrics, biochemical, and radiological parameters were measured to assess obesity, metabolic health
(assessed by the National Cholesterol Education Program –Adult Treatment Panel (NCEP-ATP III) criteria), and
subclinical measures of CVD.
Results: The prevalence of MHO was 13.5% (N = 28). No significant association with MHO was noted for age,
coronary artery calcium score, cIMT, or hs-CRP > 3 mg/dl (p = NS).
Conclusions: Our results suggest that the MHO phenotype exists in the elderly; however, subclinical CVD measures
were not different in sub-group analysis suggesting traditional metabolic risk factor algorithms may not be accurate
in the very elderly.
Keywords: Obesity, Aging, Metabolic Syndrome, Subclinical CVD

Introduction
Obesity in the elderly is rising as obese and overweight
adults continue to reach old age; however, clinically, it retains a controversial status due to the “obesity paradox”–a
term referring to increased survival rates of overweight
elderly from cardiovascular diseases as compared to their
normal weight counterparts [1]. This is complicated by the
fact that the older overweight and obese individuals are at
greater risk of developing these same diseases, often
because of the close ties between obesity and metabolic
syndrome (MetS). Within the obese population, the small
portion who do not display the typical associated metabolic
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disorders are termed “metabolically healthy obese” (MHO)
[2]. Research has yielded mixed results on the true normal
weight counterparts and others showing increased risks
[3-6]. There are few studies, however, which have examined
the prevalence of “MHO” in the very aged (≥80) population
[7-9]. In this study, we examined the MHO phenotype a
primarily octogenarian cohort and its association with
subclinical cardiovascular disease and inflammation.

Research design and methods
Subjects

This cross sectional study was conducted at the Biocardios Institute of Cardiology, Brasilia, Brazil. To participate, subjects had to be greater than 80 years of age and
free of clinical evidence of cardiovascular disease. All
participants underwent a detailed clinical examination

© 2014 Roberson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
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along with quality of life assessment including self-reported
physical activity levels.
Anthropometric & lifestyle assessment

Weight and height were measured to the nearest 0.1 kg
and 0.1 cm respectively, using standardized equipment
and procedures and the BMI calculated from these values
[10]. BMI was subdivided into “normal weight” if BMI was
less than 25, and “overweight/obese” if BMI was 25 or
greater. Waist circumference was assessed at minimal inspiration to the nearest 0.1 cm, midway between the last
rib and the iliac crest; and abdominal obesity was defined
as >88 cm for women, and 102 cm for men. Combining
Overweight (25–29.9 kg/m2), and Obese (≥30 kg/m2) into
a single category “overweight/obese” was done to increase
statistical power due to the relatively small size of the
study cohort. Overweight/obese, therefore, was defined as
BMI > = 25 and/or meeting waist circumference criteria
for abdominal obesity. Physical activity was self reported
and scored “meets recommendations” or “does not meet
recommendations” using the World Health Organization’s
“Global recommendations on physical activity for health”
information sheet [11]. This recommendation suggests
adults over the age of 65 do at least 150 minutes of
moderate-intensity aerobic physical activity per week or
75 minutes of vigorous-intensity aerobic physical activity
or an equivalent combination of moderate- and vigorousintensity activity.
Metabolic health & obesity

Details of biochemical collection methods have been published elsewhere [12]. A modified National Cholesterol
Education Program- Adult Treatment Panel III (NCEPATP III) definition of metabolic syndrome (MetS) criteria
was used to define metabolically healthy (<2 risk characteristics) verses unhealthy [13]. Systolic and diastolic blood
pressure, fasting blood glucose (FBG), HDL-C, and Triglycerides were included in the risk profile. Waist circumference was not used in the definition of MetS because it
was used as part of the definition of overweight/obesity
and it is a better indicator of obesity in the elderly for reasons described in the discussion [14]. Therefore, rather
than the traditional <3 risk characteristics cut off to be
considered “Metabolically Healthy”, a cut point of <2 risk
characteristics was utilized. Blood pressure was considered
to be “at risk” if systolic ≥130 mmHg, diastolic ≥85 mmHg,
or the subject was on antihypertensive medication. If FBG
was ≥110 mg/dL, or the subject was on diabetes medication, then FBG was considered to be “at risk”. If HDL-C
was <50 mg/dL in women, <40 mg/dL in men, or the
subject was on nicotinic acid, HDL-C was considered
“at-risk”. If Triglycerides were ≥150 mg/dL, or the subject
was on fibrates, then triglycerides were considered “at-risk”.
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Subclinical disease measures

Multidetector-row cardiac CT for coronary artery calcium
score (CACS) was used to detect subclinical atherosclerosis.
Those with a CACS = 0 were considered “normal”, which
is associated with a low risk of CVD events in literature
[15]. CACS >0 were subdivided into 3 groups (0–100;100–
400 and >400) in an attempt to determine differences in
scores across groups. Carotid sonography was used to
examine intima-media thickness (CIMT) and was analyzed
as a continuous variable. High-sensitivity C reactive protein
(hs-CRP) and uric acid was measured to assess degree of
underlying inflammation and endothelial function.
Statistical analysis

The analyses compared the four metabolic and weight
phenotypes and measures of demographics, subclinical
disease, and metabolic risks using chi-square for categorical variables and ANOVA for normally distributed continuous variables. Ten year Framingham risk scores were
calculated as per published literature [16]. Pair wise comparisons were tested when significant differences were
found. For skewed continuous data, the Kruskal-Wallis
test was used. A p-value <0.05 was considered statistically
significant.

Results
MHO and Subclinical CVD

The cross sectional study population consisted of 208
individuals (79% Female), age 80 and older (mean age 84 ±
4, range 80–102). Overall, 9.0% of men and 14.6% of
women were considered to be MHO. The most common
metabolic syndrome components were abnormal blood
pressure, followed by high waist circumference, and low
HDL. When analyzed by four categories inclusive of
metabolic clustering and weight, there were no significant differences between metabolically healthy, normal
weight (MHNW); metabolically unhealthy, normal weight
(MUNW); MHO; and metabolically unhealthy obese/overweight (MUHO) in most subclinical measures of CVD,
inflammation, and age (Table 1). Only median Uric Acid
was significantly different across the four groups; however,
when it was categorized into clinically relevant categories
(>6 mg/dL or ≤6 mg/dL), these differences became null
due to small sample size. When CACS was categorized
into 0, 1–100, 100–400, ≥400 no relationships were found
with metabolic status or obesity. A total of 21 (11.9%)
adults were found to have calcium scores of 0.

Discussion
In this very elderly Brazilian population, the prevalence
of metabolically healthy obesity was 13.5% overall. Our
results are somewhat in contrast to those reported by
Wildman et al. who examined the prevalence of the
MHO phenotype in the NHANES database, including

Overall
N = 208

1. Metabolically
healthy normal
weight
(N = 21; 10.1%)

2. Metabolically unhealthy
normal weight
(N = 43; 20.7%)

3. Metabolically
healthy overweight/obese
(N = 28; 13.5%)

4. Metabolically unhealthy
overweight/obese
(N = 116; 55.8%)

Overall
p-values

Age, yrs
(median, IQR)

83 (81,87)

85 (82,87)

83 (81,87)

84 (81,89)

83 (81,87)

0.55

Gender (Female),
n (%)

164 (79)

13 (62)c

29 (67)e

24 (86)

98 (84)c,e

0.02

BMI, kg/m2
(median, IQR)

26 (23,29)

22 (20,23)b,c

23 (21,24)d,e

26 (24,30)b,d

28 (26,31)c,e

0.000

Current Smokers,
n (%)

5 (2)

0 (0)

1 (2)

1 (4)

3 (3)

0.87

Physical Activity
Reaches WHO
recommendation, n (%)

54 (27)

8 (40)

13 (32)

8 (29)

25 (22)

0.33

Systolic Blood Pressure,
mmHg (median, IQR)

142 (132,57)

139 (119,145)

140 (129,165)

136 (131,151)

143 (135,157)

0.12

Diastolic Blood Pressure,
mmHg (median, IQR)

73 (67,82)

74 (66,74)

71 (67,80)

73 (67,83)

75 (68,84)

0.72

“At Risk” Blood Pressure,
n (%)

129 (62)

11 (52)a,b,c

38 (88)a,e

25 (89)b,f

115 (99)c,e,f

0.000

HbA1C (median, IQR)

6.0 (5.7,6.3)

5.8 (5.6,6.1)

5.8 (5.6,6.3)

5.7 (5.5,6.1)

6.1 (5.8,6.5)

0.02

Fasting Blood Glucose,
mg/dL (median, IQR)

95 (89,105)

93 (86,96)

95 (89,107)

91 (85,93)

99 (89,113)

0.03

“At Risk” Fasting Blood
Glucose, n (%)

40 (25)

3 (10)a,c

11 (34)a,d

0 (0)d,f

28 (36)c,f

0.000

Total Cholesterol,
mg/dL (mean, SD)

198 (41)

220 (36)

190 (40)

207 (29)

196 (44)

0.03

LDL Cholesterol, mg/dL
(mean, SD)

114 (36)

132 (33)

108 (37)

117 (23)

112 (38)

0.09

HDL Cholesterol mg/dL
(median, IQR)

54 (45,63)

62 (56,70)c

55 (45,63)

60 (54,67)f

49 (42,60)c,f

0.000

“At Risk” HDL, n (%)

65 (31)

0 (0)a,c

14 (33)a,d

0 (0)d

51 (44)c

115 (90,156)

104 (91,119)

105 (88,152)

100 (83,113)

“At Risk” Triglycerides,
n (%)

123 (59.4)

2 (10)a,c

30 (70)a,d

Waist Circumference,
cm (mean, SD)

94.22 (12.1)

80.4 (7.3)b,c

129 (62.3)

0 (0)b,c

0.000
f

134 (99,167)

0.000

1 (4)d,f

90 (78)c,f

0.000

83.9 (8.5)d,e

95.8 (10.0)b,d

100.1 (9.6)c,e

0.000

0 (0)d,e

23 (82.1)b,d

106 (91.4)e,c

0.000
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Triglycerides, mg/dl
(median, IQR)

f
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Table 1 Metabolic Health, Obesity Status, and Subclinical Disease in the study population

“At Risk” Waist
Circumference,
n (%)
Framingham Risk Score
(median, IQR)

31 (20,48)

27 (21,37)

32 (20,51)

23 (17,35)

34 (21,50)

0.02

hs-CRP mg/dL
(median, IQR)

1.9 (1.0,3.4)

1.9 (1.0,3.8)

1.5 (1.0,3.3)

1.8 (1.1,2.6)

2.1(1.0,3.9)

0.51

hs-CRP > 3 mg/dL, n (%)

66 (32)

7 (33)

13 (30)

4 (14)

42 (37)

0.15

Uric Acid, mg/dL (median, IQR)

5.1 (4.4,6.0)

4.9 (3.9,5.5)

5.0 (4.3,5.7)

5.7 (5.5,6.1)

5.3 (4.6,6.4)

0.01

Uric Acid >6 mg/dL,
n (%)

52 (25)

3 (14)

7 (16)

4 (14)

38 (33)

0.06

Right CIMT, mm
(mean, SD)

0.82 (0.15)

0.94 (0.23)

0.79 (0.12)

0.80 (0.09)

0.81 (.15)

0.14

Left CIMT, mm (mean, SD)

0.86 (0.17)

0.91 (0.18)

0.85 (0.14)

0.87 (0.09)

0.84 (0.20)

0.43

CACS, Agatston (median, IQR)

142 (34,424)

176 (73,698)

70 (11,474)

162 (46,403)

172 (36,392)

0.36

CACS = 0, n (%)

21 (12)

2 (10)

3 (8)

3 (12)

13 (14)

0.68

CACS = 1-100, n (%)

57 (32)

5 (26)

18 (46)

9 (34)

25 (27)

CACS = 100-400, n (%)

53 (30)

6 (32)

8 (20)

7 (27)

32 (34)

CACS ≥ 400, n (%)

46 (26)

6 (32)

10 (26)

7 (27)

23 (25)
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Table 1 Metabolic Health, Obesity Status, and Subclinical Disease in the study population (Continued)

a

= p < 0.05 between groups 1 and 2; b = p < 0.05 between groups 1 and 3; c = p < 0.05 between groups 1 and 4; d = p < 0.05 between groups 2 and 3; e = p < 0.05 between groups 2 and 4; f = p < 0.05 between groups
3 and 4.
BMI = body mass index; WHO = world health organization; HbA1C = glycated hemoglobin; CACS = coronary artery calcium score; CIMT = carotid intima media thickness; hs-CRP = high sensitivity c-reactive protein.
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those aged 80 years and above. Among normal weight
individuals, 67% of our population was metabolically unhealthy compared with 56% in the NHANES population.
Among the obese, 81% of participants were found to be
metabolically unhealthy compared to 22% reported by
Wildman et al. These differences may be due to the
smaller size of our sample, or due to the different criteria for obesity in our study or may represent an ethnic
difference in the prevalence of these phenotypes. Further
studies are needed in order to determine the true prevalence of these phenotypes in the very elderly population
[17].
When we examined our metabolic risk factors independently, we found that high blood pressure was very
common (62%), correlating with previous reports indicating rates of 60-80% in the elderly [12]. Low HDL and
high triglycerides were present in over half of the population. High fasting plasma glucose was present in just
over one quarter. As one can see from the data, risk
factors become less useful at predicting events as most
elderly people have at least one “at risk” condition. Using
these risk factors to stratify this population into higher
or lower risk categories therefore becomes much more
difficult.
The degree of subclinical CVD assessed by mean calcium score, CIMT, and inflammation were no different
among the four metabolic categories. CACS has been
shown to be superior to risk factors in predicting CVD
risk in literature, both independently and as an addition
to risk factor scores [18-21], although no consensus has
been reached on the same. Newman et al. studied CACS
in older adults and found that hypertension, diabetes,
total, LDL, and HDL cholesterol levels were not significantly different across the levels of calcium score [22],
suggesting that traditional risk factors may not be associated with subclinical atherosclerosis in the very elderly.
Our study is in partial agreement, in that there are significant differences in risk factor prevalence across
groups, but these have not translated into a difference in
subclinical disease burden across groups. Literature has
identified a number of age related changes in biological
processes underlying atherogenesis in the elderly, possibly diminishing the utility of traditional factors - which
may be responsible for our results [23-26]. Alternatively,
it is possible that the markers of subclinical disease used
in our study become less useful with advancing age, although we are not aware of any literature documenting
the same. Interestingly, 11.9% of our cohort were found
to have calcium scores of 0 which has been associated
with a very small risk of a CVD event in the literature
[15]. This raises the interesting possibility that these
individuals with CACS = 0 may represent a subgroup in
our population with an extremely low “natural” or “baseline” risk of CVD, deserving of further exploration.
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Limitations

This study was a cross-sectional survey which only examined the subjects at one time point. While this allows
us to examine the prevalence of the MHO phenotype in
people aged 80 years and above and its association with
subclinical CVD, it does not allow us to establish a temporal relationship without follow-up studies. Another
limitation of our study was the small sample size. Living
into the 8th decade of life is in itself rare, and being free
of cardiovascular disease at that time is even more
uncommon. Having data on only 208 individuals limited
the power to interpret the results of our study. Future,
larger studies may bring out differences in subclinical
disease across metabolic risk/weight groups which were
null in our study and have the power to examine groups
in context of increasing number of metabolic risks. This
would help identify the most predictive traits among the
elderly, and perhaps enable researchers to eliminate
extraneous risk factors in this understudied group.
Usefulness of BMI to diagnose obesity in the elderly is
poor due to a weight instability and sarcopenia (or
muscle wasting) in the very elderly [27]. The elderly
population is known to be subject to involuntary weight
loss, with as much as 15-20% of the elderly losing 5% of
their total body weight over 5–10 years [28]. Additionally, published literature has suggested that different
BMI cutoffs may be more appropriate for the very elderly (in which BMI range of 22–29 kg/m2 is considered
normal) [29]. Using BMI as an indicator of obesity with
cutoffs of >25 kg/m2 may have caused confounding in
our results and blunting of the associations. As people
age (especially after the age of 65), muscle tissue is lost
and replaced with metabolically active adipose tissue.
Sarcopenic obesity has been coined to describe the condition of excess fat without the accompanying increase
in extra skeletal muscle to support the weight seen in
younger individuals [1]. This makes older people more
likely to be considered obese by body fat standards and
less likely using traditional BMI.
Our study was also subject to survivorship bias.
Subjects over the age of 80 represent a small fraction of
their initial birth cohort, meaning they possessed some
unique trait giving them a survival advantage over their
peers, allowing them to reach the age of 80. This unstudied trait may have protected them from cardiovascular disease in their life course, which would help explain
the wide variability in risk profiles. Additionally, most of
our population was female (79%), which limits the
generalizability of our findings.

Conclusion
Our study demonstrates significant differences in metabolic risk factor prevalence across obesity phenotypes
without corresponding differences in subclinical disease
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burden or inflammatory activity in the very elderly. When
assessing high risk populations such as the very elderly,
the usefulness of traditional risk factor assessment (such
as Framingham) should be carefully questioned. Most
people >80 have at least one metabolic risk factor, which
may limit the ability of employing risk factors alone in an
attempt to stratify population into different risk categories.
Therefore, actual measures of subclinical disease are
potentially important as they provide a snapshot of disease
progression and more accurate event prediction. However,
our study did not document any significant differences in
subclinical disease burden across groups. Since our study
is a cross-sectional one, it is beyond the scope of the
present study to determine if the traditional risk factors or
subclinical measures are a correct representation of this
population’s risk. This study identified the existence of the
MHO phenotype within this population; however, failed to
show an association between the metabolic phenotype and
the subclinical cardiovascular disease burden despite significant differences in traditional risk factor profiles. Few
studies have examined the clinical utility and additional
risk prediction of subclinical disease measures in the very
elderly, and none in association with metabolic syndrome
and obesity. Future long term follow up studies are needed
to elucidate the connection between metabolically healthy
obesity, the progression of cardiovascular disease, and ultimately, morbidity and mortality in this rapidly expanding
population.
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